INS and diabetes mellitus: Group A: isotype control antibody and oral diluent; group B: oral insulin (1 mg twice weekly×6 weeks) starting 2–5 days after diabetes onset; group C: anti-CD20 Mab (10 mg/kg IP on days 1–4); group D: oral insulin plus anti-CD20 Mab (regimens as for groups B and C); group E: same as group D but oral insulin was delayed to start on day 21; and group F: treatment with anti-CD3 Mab (5 μg on days 1–5) as positive control.